Dynamic Technology Lab Private Ltd Increases Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Dynamic Technology Lab Private Ltd raised its stake in Illumina, Inc. (NASDAQ:ILMN) by 110.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,471 shares of the life sciences company’s stock after acquiring an additional 3,924 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Illumina were worth $998,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in ILMN. Golden State Wealth Management LLC acquired a new stake in shares of Illumina in the 4th quarter valued at about $32,000. Versant Capital Management Inc lifted its stake in Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after buying an additional 146 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of Illumina in the fourth quarter valued at approximately $45,000. Assetmark Inc. grew its position in shares of Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after acquiring an additional 296 shares during the last quarter. Finally, Lee Danner & Bass Inc. acquired a new position in shares of Illumina in the 4th quarter valued at $48,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on ILMN shares. Robert W. Baird lowered their price objective on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 5th. HSBC downgraded shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 target price on the stock. in a report on Friday, February 28th. Citigroup cut their price target on shares of Illumina from $130.00 to $90.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Stephens reissued an “overweight” rating and set a $156.00 target price on shares of Illumina in a research note on Tuesday, March 11th. Finally, Hsbc Global Res downgraded Illumina from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Illumina has a consensus rating of “Moderate Buy” and a consensus price target of $140.90.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $74.16 on Friday. The business has a fifty day simple moving average of $96.82 and a 200-day simple moving average of $125.06. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 52 week low of $70.64 and a 52 week high of $156.66. The company has a market cap of $11.75 billion, a P/E ratio of -9.66, a P/E/G ratio of 1.60 and a beta of 1.38.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Equities research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.